Luces y sombras de la Guía Europea ESC-2021 de Prevención de la Enfermedad Cardiovascular en la Práctica Clínica
e202308064
Palabras clave:
Enfermedad vascular, Factores de riesgo, Riesgo vascular, Escalas de riesgo, Predicción del riesgo, Riesgo residual, Guías de práctica clínica, Riesgo competitivoResumen
Los médicos de familia atienden un importante número de pacientes con alto riesgo vascular (RV). Las Guías Europeas de Prevención Cardiovascular (2021) proponen una nueva clasificación del riesgo y estrategias de intervención sobre los factores de riesgo (FRV), orientada a la toma de decisiones compartidas entre profesionales y pacientes. En el presente trabajo realizamos un análisis crítico de dichas guías, ofreciendo posibles soluciones prácticas para la Atención Primaria.
Son destacables aspectos positivos (luces) que los modelos de RV SCORE2 (entre cuarenta y sesenta y nueve años) y SCORE2-OP (entre setenta y ochenta y nueve años) se basan en cohortes más actuales y miden con mayor exactitud y discriminación dicho riesgo. Además, se propone actuar diferenciadamente sobre el riesgo según la edad. Pragmáticamente, se presentan nuevos modelos informáticos para calcular el riesgo. Sin embargo, entre los aspectos negativos (sombras), parece colegirse una mayor dificultad de implementación al proponerse nueve subgrupos de sujetos según su edad o nivel de riesgo, con un dintel definitorio de alto RV subjetivo que podría ocasionar un incremento sustancial en el número de sujetos susceptibles de tratar sin una discriminación objetiva que lo sustente. Además, las intervenciones sobre los FRV en dos pasos podrían retrasar la consecución de objetivos terapéuticos, sobre todo en pacientes de muy alto riesgo, diabéticos o con enfermedad cardiovascular.
Ante las dificultades que plantea la valoración del riesgo, proponemos unificar criterios y simplificar los mensajes claves para hacer unas guías más atractivas y que realmente ayuden a los profesionales de Atención Primaria en su práctica habitual.
Descargas
Citas
Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42:3227-3337. http://dx.doi.org/10.1093/eurheartj/ehab484
Brotons C. Las tablas de riesgo cardiovascular. Presente y futuro. Hipertens riesgo vasc.2019;36(4):173-175. https://dx.doi.org/10.1016/j.hipert.2019.10.001
Damen JAAG, Hooft L, Schuit E, Debray TP, Collins GS, Tzoulaki I et al. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ. 2016;353:i2416. http://dx.doi.org/10.1136/bmj.i2416
Studziński K, Tomasik T, Krzysztoń J et al. Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: an overview of systematic reviews. BMC Cardiovasc Disord. 2019;19:11. http://dx.doi.org/10.1186/s12872-018-0990-2
Karmali KN, Persell SD, Perel P, Lloyd-Jones DM, Berendsen MA, Huffman MD. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;14;3:CD006887. http://dx.doi.org/10.1002/14651858.CD006887.pub4
Arrarte V, Campuzano R, Alarcón Duque JA, Aldama G, Barrios V, Bonanad C, Castro-Conde A et al., Grupo de Trabajo de la SEC para la guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica y Comité de Guías de la SEC. Comentarios a la guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. Rev Esp Cardiol. 2022;75:364-369. http://dx.doi.org/10.1016/j.recesp.2021.10.015
Brotons C, Camafort M, Castellanos MM, Clarà A, Cortés O, Díaz Rodríguez A et al. Comentario del CEIPV a las nuevas guías europeas de prevención cardiovascular 2021. Rev Esp Salud Pública. 2022;96:e1-14. [Consultado 15 Dic 2022]. Disponible en: https://scholar.google.com/scholar?cluster=8759780254494231875&hl=es&as_sdt=0,5
Peña MJ, Drak Y, Egocheaga MI. Guías europeas de prevención cardiovascular 2021. Med Gen Fam. 2022;11(2):93-96. http://dx.doi.org/10.24038/mgyf.2022.018
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42:2439-2454. http://dx.doi.org/10.1093/eurheartj/ehab309
The SCORE2-OP working group and ESC Cardiovascular Risk Collaboration (CRC) Unit. SCORE2-OP risk prediction algorithms: estimating incidence cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021;42:2455-2467. http://dx.doi.org/10.1093/eurheartj/ehab312
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). EurHeart J. 2016;37:2315-2381. http://dx.doi.org/10.1093/eurheartj/ehw106
Piepoli MF, Abreu A, Albus C Ambrosetti M, Brotons C, Catapano AL et al. Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. Eur J PrevCardiol. 2020;27:181-205. http://dx.doi.org/10.1177/2047487319893035
Conroy RM, Pyörälä K, Fitzgerald AE, Sans S, Menotti A, De Backer G et al., SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. EurHeart J. 2003;24:987-1003. http://dx.doi.org/10.1016/S0195-668X(03)00114-3
Cooney MT, Selmer R, Lindman A, Tverdal A, Menotti A, Thomsen T et al. Cardiovascular disease risk estimation in older persons: SCORE O.P. Eur J Prev Cardiol. 2016;23:1093-1103. http://dx.doi.org/10.1177/2047487315588390
Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol. 2009;54(14):1209-1227. http://dx.doi.org/10.1016/j.jacc.2009.07.020
Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017; 357:j2099. http://dx.doi.org/10.1136/bmj.j2099
Dziopa K, Asselbergs FW, Gratton J, Chaturvedi N, Schmidt AF. Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settings. Diabetologia. 2022;65:644-656. http://dx.doi.org/10.1007/s00125-021-05640-y
Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015;12:e1001779. http://dx.doi.org/10.1371/journal.pmed.1001779
Danesh J, Erqou S, Walker M, Thompson SG, Tipping R, Ford C et al., Emerging Risk Factors Collaboration. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol. 2007;22:839-869. http://dx.doi.org/10.1007/s10654-007-9165-7
Gómez-Gerique JA, Gutiérrez-Fuentes JA, Montoya MT, Porres A, Rueda A, Avellaneda A et al. Lipid profile of the Spanish population: the DRECE (diet and risk of cardiovascular disease in Spain) study. DRECE study group. Med Clin (Barc). 1999;113:730-735. https://pubmed.ncbi.nlm.nih.gov/10680124/
Ibáñez AM, Caamaño MB, Fernández MVF, Sánchez JT, Arenal JMC, González Ramos JS et al. Risk Factors for cardiovascular and ischaemic heart disease in a Mediterranean country. Clin Drug Investig. 2002;22:241-251. http://dx.doi.org/10.2165/00044011-200222040-00004
Danesh J, Saracci R, Berglund G, Feskens E, Overvad K, Panico S et al. EPIC-Heart. EPIC-Heart: the cardiovascular component of a prospective study of nutritional, lifestyle and biological factors in 520,000 middle-aged participants from 10 European countries. Eur J Epidemiol. 2007;22(2):129-141. http://dx.doi.org/10.1007/s10654-006-9096-8
Naess O, Søgaard AJ, Arnesen E, Beckstrøm AC, Bjertness E, Engeland A et al. Cohort profile: cohort of Norway (CONOR). Int J Epidemiol. 2008;37:481-485, http://dx.doi.org/10.1093/ije/dym217
Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van ST, Smeeth L. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44:827-836. http://dx.doi.org/10.1093/ije/dyv098
Bulpitt C, Fletcher A, Beckett N, Coope J, Gil-Extremera B, Forette F et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging. 2001;18:151-164. http://dx.doi.org/10.2165/00002512-200118030-00001
Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM et al.,PROSPER study group.Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630. http://dx.doi.org/10.1016/s0140-6736(02)11600-x
The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129:687-702. http://dx.doi.org/10.1093/oxfordjournals.aje.a115184
Bild DE, Bluemke DA, Burke GL, Detrano R, Diez-Roux AV, Folsom AR et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:871-881. http://dx.doi.org/10.1093/aje/kwf113
Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM et al., SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016;315:2673-2682. http://dx.doi.org/10.1001/jama.2016.7050
Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J.1991;121(1 Pt 2):293-298. https://dx.doi.org/10.1016/0002-8703(91)90861-b
Marrugat J, Solanas P, D’ Agostino R, Sullivan L, Ordovas J, Cordón F et al. Estimación del riesgo coronario en España mediante la función de Framingham calibrada. Rev Esp Cardiol.2003;56:253-261. https://dx.doi.org/10.1016/S0300-8932(03)76861-4
Marrugat J, Vila J, Baena JM, Grau M, Sala J, Ramos R et al. Validez relativa de la estimación del riesgo cardiovascular a 10 años en una cohorte poblacional del studio REGICOR. Rev Esp Cardiol. 2011;64(5):385-394, https://dx.doi.org/10.1016/j.recesp.2010.12.011
Rzepka-Cholasinska A, Kasprzak M, Michalski P, Pietrzykowski L, Grzelakowska K, Kubica A. Cardiovascular riskassessmentbasedon SCORE and SCORE2. Med Res J. 2022;7:164-169. http://dx.doi.org/10.5603/MRJ.2022.0027
Barkas F, Sakkou SF, Styla C, Anastasiou G, Koutsogianni AD, Liamis G, Liberopoulos E. Clinical application of the new cardiovascular risk prediction algorithms SCORE2 and SCORE2-OP in patients with dyslipidemia. Eur J PrevCardiol. 2022;29(Suppl 1):zwac056.142. http://dx.doi.org/10.1093/eurjpc/zwac056.142
Csenteri O, Jancsó Z, Szöllösi GJ, Andréka P, Vajer P. Differences of cardiovascular risk assessment in clinical practice using SCORE and SCORE2. Open Heart. 2022;9:e002087. http://dx.doi.org/10.1136/openhrt-2022-002087
Mortensen MB, Tybjærg-Hansen A, Nordestgaard BG. Statin eligibility for primary prevention of cardiovascular disease according to 2021 European prevention guidelines compared with other international guidelines. JAMA Cardiol. 2022;7:836-843.
Ortiz A, Wanner C, Gansevoort R, ERA Council. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. Eur J PrevCardiol. 2022;29(17):2211-2215. http://dx.doi.org/10.1093/eurjpc/zwac186
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:5-14, http://dx.doi.org/10.1038/kisup.2012.77
Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, Thompson A et al., Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377:1085-1095. http://dx.doi.org/10.1016/S0140-6736(11)60105-0
Mancusi C, Losi MA, Izzo R, Canciello G, Carlino MV, Albano G et al. Higher pulse pressure and risk for cardiovascular events in patients with essential hypertension: The Campania Salute Network. Eur J Prev Cardiol. 2018;25:235-243. http://dx.doi.org/10.1177/2047487317747498
Melgarejo JD, Thijs L, Wei DM, Bursztyn M, Yang WY, Li Y et al., The International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcome Investigators. Relative and absolute risk to guide the management of pulse pressure, an age-related cardiovascular risk factor. Am J Hypertens. 2021;34:929-938. http://dx.doi.org/10.1093/ajh/hpab048
Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts. The MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) Biomarker Project. Circulation. 2010;121:2388-2397. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.901413
Mostaza JM, Pintó X, Armario P, Masana L, Real JT, Valdivielso P et al. SEA 2022 Standards for global control of cardiovascular risk. ClinInvestigArterioscler. 2022;34:130-179. http://dx.doi.org/10.1016/j.arteri.2021.11.003
Gidding SS, Colangelo LA, Nwabuo CC, Lewis CE, Jacobs DR, Schreiner PJ et al. PDAY risk score predicts cardiovascular events in young adults: the CARDIA study. Eur Heart J. 2022;43:2892-2900. http://dx.doi.org/10.1093/eurheartj/ehac009
Dorresteijn JA, Visseren FL, Wassink AM, Gondrie MJ, Steyerberg EW, Ridker PM et al., SMART Study Group. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart. 2013;99:866-872. http://dx.doi.org/10.1136/heartjnl-2013-303640
DIAL2 working group. Estimating individual lifetime risk of incident cardiovascular events in adults with type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2). Eur J PrevCardiol. 2023;30(1):61-69. http://dx.doi.org/10.1093/eurjpc/zwac232
Kotseva K, De Backer G, De Bacquer D, Ryden L, Hoes A, Grobbee D et al. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. Eur J PrevCardiol. 2021;28:370-379. http://dx.doi.org/10.1177/2047487320908698
Nicole EM, Jaspers NEM, Blaha MJ, Matsushita K, van der Schouw YT, Wareham NJ et al. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. Eur Heart J. 2020;41:1190-1199. http://dx.doi.org/10.1093/eurheartj/ehz239
De Bacquer D, Ueda P, Reiner Ž, De Sutter J, De Smedt D, Lovic D et al. EUROASPIRE IV and V National Coordinators. Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. Eur J PrevCardiol. 2022 Mar 11;29(2):328-339
Wakabayashi K, Suzuki H, Fukumoto Y, Obara H, Kakuma T, Sakuma I et al. Comorbidities associated with residual cardiovascular risk in patients with chronic coronary syndrome receiving statin therapy- subanalysis of the REAL-CAD Trial. Circ Rep. 2022;4:422-428. http://dx.doi.org/10.1253/circrep.CR-22-0070
Ascaso JF, Millán J, Hernández-Mijares A, Blasco M, Brea A, Díaz A et al. Documento de consenso sobre el manejo de la dislipemia aterogénica de la Sociedad Española de Arteriosclerosis. Clin Investig Arterioscler. 2017;29:86-91. http://dx.doi.org/10.1016/j.arteri.2016.11.001
Bertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr. 2017;25. https://dx.doi.org/10.1186/s13098-017-0225-1
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol. 2012;19(4):585-667. https://dx.doi.org/10.1177/2047487312450228
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. https://dx.doi.org/10.1093/eurheartj/ehz486
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. https://dx.doi.org/10.1016/j.atherosclerosis.2019.08.014
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM et al. Hyperglycemia in Type 2 Diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. https://doi.org/10.2337/dci22-0034
Emerging Risk Factor Collaboration. Sarwar N, Gao P, Seshasai SR, Ingelsson E, Lawlor DA, Angelantonio E et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet.2010;375:2215-2222. https://dx.doi.org/10.1016/S0140-6736(10)60484-9
Sattar N, Rawshani A, Franzén S, Rawshani A, Svensson AM, Rosengren A. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation. 2019;139(19):2228-2237. https://dx.doi.org/10.1161/CIRCULATIONAHA.118.037885
Cigolle CT, Blaum CS, Lyu C, Ha J, Kabeto M, Zhong J. Associations of age at diagnosis and duration of diabetes with morbidity and mortality among older adults. JAMA Netw Open. 2022 ;5(9):e2232766. https://dx.doi.org/10.1001/jamanetworkopen.2022.32766
Nanayakkara N, Curtis AJ, Heritier S, Gadowski AM, Pavkov ME, Kenealy T et al. Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia. 2021;64(2):275-287. https://dx.doi.org/10.1007/s00125-020-05319-w
De Jong M, Woodward M, Peters SAE. Duration of diabetes and the risk of major cardiovascular events in women and men: A prospective cohort study of UK Biobank participants. Diabetes Res Clin Pract. 2022;188:109899. https://dx.doi.org/10.1016/j.diabres.2022.109899
Li FR, Yang HL, Zhou R, Zheng JZ, Chen GC, Zou MC et al. Diabetes duration and glycaemic control as predictors of cardiovascular disease and mortality. Diabetes ObesMetab. 2021;23(6):1361-1370. https://dx.doi.org/10.1111/dom.14348
Wang Y, O’Neil A, Jiao Y, Wang L, Huang J, Lan Y et al. Sex differences in the association between diabetes and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic review and meta-analysis of 5,162,654 participants. BMC Med. 2019;17(1):136. https://dx.doi.org/10.1186/s12916-019-1355-0
Xu G, You D, Wong L, Duan D, Kong F, Zhang X, Zhao J et al. Risk of all-cause and CHD mortality in women versus men with type 2 diabetes: a systematic review and meta-analysis. Eur J Endocrinol. 2019;180(4):243-255. https://dx.doi.org/10.1530/EJE-18-0792
Kengne AP, Patel A, Marre M, Travert F, Lievre M, Zoungas S et al., ADVANCE Collaborative Group. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J CardiovascPrevRehabil. 2011;18:393-398. http://dx.doi.org/10.1177/1741826710394270
Berkelmans GFN, Gudbjörnsdottir S, Visseren FLJ, Wild SH, Franzen S, Chalmers J et al. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with type 2 diabetes mellitus. Eur Heart J. 2019;40:2899. http://dx.doi.org/10.1093/eurheartj/ehy839
Cersosimo E, Johnson EL, Chovanes C, Skolnik N. Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. Diabetes ObesMetab. 2018;20:497-507. https://dx.doi.org/10.1111/dom.13108
Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G et al., DA VINCI study. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279-1289. https://dx.doi.org/10.1093/eurjpc/zwaa047
Kytö V, Rautava P, Tornio A. Initial statin dose after myocardial infarction and long-term cardiovascular outcomes. Eur Heart J CardiovascPharmacother. 2022:pvac064. Online ahead of print. https://dx.doi.org/10.1093/ehjcvp/pvac064
Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A et al. SECURE Investigators. Polypillstrategy in secondary cardiovascular prevention. N Engl J Med. 2022 ;387(11):967-977. https://dx.doi.org/10.1056/NEJMoa2208275
Brotons C. The challenge of therapy adherence in clinical practice. Eur J Prev Cardiol. 2022:zwac197. https://dx.doi.org/10.1093/eurjpc/zwac197
Matsushita K, Kaptoge S, Hageman SHJ, Sang Y, Ballew SH, Grams ME et al. Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP. Eur J Prev Cardiol. 2023;30(1):8-16. https://dx.doi.org/10.1093/eurjpc/zwac176
Ankle Brachial Index Collaboration; Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197-208. https://dx.doi.org/10.1001/jama.300.2.197
Publicado
Cómo citar
Número
Sección
Categorías
Licencia
Derechos de autor 2023 Enrique Martín-Rioboó, Carlos Brotons-Cuixart, Antonio Ruiz García, Fátima Villafañe Sanz, Manuel Frías Vargas, Ana Moyá Amengual, Juan Antonio Divisón Garrote, María Cruz Seoane Vicente, José R. Banegas, Vicente Pallarés Carratalá
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
